The 4 Biosimilar Drugs for Avastin (and What to Know About …
Jan 23, 2023 · Four biosimilar versions of Avastin are currently approved: Mvasi (bevacizumab-awwb), Zirabev (bevacizumab-bvzr), Alymsys (bevacizumab-maly), and Vegzelma (bevacizumab-adcd). Avastin’s biosimilars may help you save money on your treatment without sacrificing safety or effectiveness.
FDA approves first biosimilar for the treatment of cancer
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer.
Avastin® (bevacizumab) Biosimilar | MVASI® (bevacizumab …
Find out more about MVASI® (bevacizumab), an Avastin® biosimilar. See Important Safety & Prescribing Info including Boxed Warnings
Official Patient Website | ZIRABEV™ (bevacizumab-bvzr) | Safety …
Learn about ZIRABEV™ (bevacizumab-bvzr), an FDA-approved biosimilar of Avastin® (bevacizumab), on the official patient website.
FDA Approves Avzivi, the Fifth Biosimilar to Avastin
Dec 19, 2023 · The FDA has approved the fifth bevacizumab biosimilar, Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) for the treatment of several types of cancer. Avzivi is a humanized monoclonal antibody that inhibits vascular endothelial growth factor and references Genentech’s Avastin (bevacizumab).
Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, …
Jun 28, 2019 · Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ZIRABEV™ (bevacizumab-bvzr), a biosimilar to Avastin ® (bevacizumab), 1 for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell ...
Comparison of efficacy and safety of bevacizumab biosimilar and ...
Jan 10, 2022 · In recent years, biosimilar bevacizumab has been developed gradually and achieved good results. Therefore, this study aimed to evaluate the efficacy and safety of biosimilar bevacizumab versus the original drug in patients with non-squamous NSCLC by collating available data from head-to-head RCTs.
Efficacy and Safety of Bevacizumab Biosimilars Compared With …
Jul 5, 2022 · We systematically summarized the current evidence for the efficacy and safety of bevacizumab biosimilars in patients with advanced non-small cell lung cancer (NSCLC) or metastatic colorectal cancer (CRC).
Bevacizumab Biosimilar Avzivi Receives FDA Approval
Dec 14, 2023 · The US Food and Drug Administration (FDA) has approved Avzivi (bevacizumab-tnjn), a biosimilar to Avastin (bevacizumab). Avzivi is a VEGF inhibitor indicated for the treatment of: Metastatic...
FDA approves first biosimilar for cancer treatment | FDA
On Sept. 14, 2017, the U.S. Food and Drug Administration approved Mvasi (bevacizumab-awwb, Amgen Inc.) as a biosimilar to Avastin (bevacizumab, Genentech Inc.).